Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies.
Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M.
Roeker LE, et al. Among authors: thompson mc.
Acta Haematol. 2024 Jun 1. doi: 10.1159/000539587. Online ahead of print.
Acta Haematol. 2024.
PMID: 38824917